| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
During the last three months, 7 analysts shared their evaluations of United Therapeutics (NASDAQ:UTHR), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $310.43, with a high estimate of $400.00 and a low estimate of $240.00. This current average has increased by 5.05% from the previous average price target of $295.50.
The perception of United Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jessica Fye | JP Morgan | Raises | Overweight | $300.00 | $280.00 |
| Chris Shibutani | Goldman Sachs | Raises | Neutral | $240.00 | $218.00 |
| Hartaj Singh | Oppenheimer | Raises | Outperform | $400.00 | $375.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $300.00 | - |
| Tiago Fauth | Wells Fargo | Raises | Overweight | $325.00 | $309.00 |
| Liana Moussatos | Wedbush | Maintains | Outperform | $308.00 | - |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $300.00 | - |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into United Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on United Therapeutics analyst ratings.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: United Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 33.7%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: United Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 45.24%, the company may face hurdles in effective cost management.
Return on Equity (ROE): United Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 5.42%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): United Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 4.49%, the company may face hurdles in achieving optimal financial performance.
Debt Management: United Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: UTHR
